(Q38012499)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22621256%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

title

Developing histone deacetylase inhibitors in the therapeutic armamentarium of pancreatic adenocarcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22621256%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference

Ganji Purnachandra Nagaraju

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22621256%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

author name string

Syed F Zafar

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22621256%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Bassel El-Rayes

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22621256%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

language of work or name

English

0 references

publication date

24 May 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22621256%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Therapeutic Targets

2 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22621256%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22621256%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22621256%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

page(s)

707-718

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22621256%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Surgical treatment of pancreatic cancer: the role of adjuvant and multimodal therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Collaborative spirit of histone deacetylases in regulating chromatin structure and gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Translating the Histone Code

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Lysine acetylation targets protein complexes and co-regulates major cellular functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Developing histone deacetylase inhibitors as anti-cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

The many roles of histone deacetylases in development and physiology: implications for disease and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Mammalian sirtuins--emerging roles in physiology, aging, and calorie restriction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Histone deacetylases and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Regulation of histone deacetylase activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

HDAC2 regulates chromatin plasticity and enhances DNA vulnerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

HDACs and HDAC inhibitors in colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Histone deacetylase inhibitors: overview and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Histone deacetylase inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Bmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHA-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Vorinostat in acute myeloid leukemia and myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Targeting tumor angiogenesis with histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Histone deacetylase inhibitors: multifunctional anticancer agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

High histone deacetylase 7 (HDAC7) expression is significantly associated with adenocarcinomas of the pancreas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

The clinical development of histone deacetylase inhibitors as targeted anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Increased expression of histone deacetylase 2 is found in human gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Trichostatin A, an inhibitor of histone deacetylases, strongly suppresses growth of pancreatic adenocarcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Gene expression profiling after treatment with the histone deacetylase inhibitor trichostatin A reveals altered expression of both pro- and anti-apoptotic genes in pancreatic adenocarcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

SK-7041, a new histone deacetylase inhibitor, induces G2-M cell cycle arrest and apoptosis in pancreatic cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

NF-kappaB in cancer: from innocent bystander to major culprit

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

High expression of RelA/p65 is associated with activation of nuclear factor-kappaB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

The promise of retinoids to fight against cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Resveratrol inhibits pancreatic cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Pancreatic cancer: translational research aspects and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

A microRNA expression signature of human solid tumors defines cancer gene targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Effects of FR235222, a novel HDAC inhibitor, in proliferation and apoptosis of human leukaemia cell lines: role of annexin A1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Psammaplin A is a natural prodrug that inhibits class I histone deacetylase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Allyl mercaptan, a garlic-derived organosulfur compound, inhibits histone deacetylase and enhances Sp3 binding on the P21WAF1 promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Diallyl disulfide (DADS) increases histone acetylation and p21(waf1/cip1) expression in human colon tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Cancer chemoprevention by dietary polyphenols: promising role for epigenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Complex networks orchestrate epithelial-mesenchymal transitions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

The basics of epithelial-mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Acetylation as a transcriptional control mechanism-HDACs and HATs in pancreatic ductal adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Requirement of HDAC6 for transforming growth factor-beta1-induced epithelial-mesenchymal transition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Smad3 is key to TGF-beta-mediated epithelial-to-mesenchymal transition, fibrosis, tumor suppression and metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Combined targeting of histone deacetylases and hedgehog signaling enhances cytoxicity in pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Overexpression and localization of heat shock proteins mRNA in pancreatic carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

The Hsp90 chaperone complex as a novel target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

HSP90 and the chaperoning of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Molecular pathogenesis of pancreatic cancer and clinical perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces or

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Hsp90: the vulnerable chaperone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Autophagy fights disease through cellular self-digestion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Autophagic and apoptotic effects of HDAC inhibitors on cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Pancreatic cancers require autophagy for tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Autophagy in pancreatic cancer: an emerging mechanism of cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Gemcitabine induces the VMP1-mediated autophagy pathway to promote apoptotic death in human pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Pancreatic cancer: molecular pathogenesis and new therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Clinical development of panobinostat in classical Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473

Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691473